Dermatology

September 26, 2022

The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.

September 26, 2022

A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.

September 26, 2022

While phototherapy has been shown to have a positive effect on vitiligo as it works to reduce or prevent the destruction of skin cells, treatment done in the hospital can be long-term and require a number of visits.

August 29, 2022

The occurrence of immune-mediated inflammatory diseases (IMID) is higher in patients with inflammatory bowel disease (IBD) than in the general population.

August 27, 2022

Laser treatment presents as being highly effective for vitiligo repigmentation over other forms of treatment.

August 23, 2022

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.

May 31, 2022

Dr Bhatia concludes our discussion by outlining what factors physicians should be cognizant of when prescribing therapies to patients with AD.

May 31, 2022

A dermatology expert highlights the role JAK inhibitors play in AD therapy, from mechanism of action to ruxolitinib and the TrUE AD1 and -2 trials.

May 20, 2022

Dr Neal Bhatia explains the available treatment options for patients with AD, including their relation to guideline recommendations.

May 20, 2022

Neal Bhatia, MD, provides an overview of atopic dermatitis (AD) and the diagnostic process, as well as how its severity impacts the patient.